Program
BI 3031185
A development code.
Its studies are mostly in Borderline Personality Disorder, led by Boehringer Ingelheim.
Furthest: phase 1, since Feb 5, 20245 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 50 open or running | phase 1since Feb 5, 2024 | Feb 5, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2024First study: phase 1 study in HealthyFirst studyNCT06255340 · 75 enrolled · Germany
- Mar 27, 2025Phase 1 study in HealthyNCT06916702 · 100 enrolled · Germany
- Jun 2, 2025Phase 1 study in Borderline Personality DisorderNCT07001475 · 78 enrolled · Germany
- Oct 2, 2025Phase 1 study in HealthyNCT07211425 · 14 enrolled · Germany
- Jun 15, 2026Phase 1 study in HealthyNCT07656792 · 8 enrolled · Japan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656792Healthy · Japan | 1 | Terminated | Sep 23, 2026 | 8 |
| NCT07211425Healthy · Germany | 1 | Completed | Jan 21, 2026 | 14 |
| NCT07001475Borderline Personality Disorder · Germany | 1 | Completed | Aug 6, 2026 | 78 |
| NCT06916702Healthy · Germany | 1 | Suspended | Sep 23, 2026 | 100 |
| NCT06255340Healthy · Germany | 1 | Completed | Aug 28, 2024 | 75 |
How it is read
Names in the registry
- “BI 3031185”, 5 entries
Codes read as this program: BI3031185.
Conditions, from the studies’ own filings
- Borderline Personality Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.